HCPCS Code Descriptor:
Injection, tremelimumab-actl, 1 mg
Route of Administration:
IMJUDO is an Oncology drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The C Code: C9147 is aligned to the drug IMJUDO.